US-based Gilead Sciences has roped in four Indian pharmaceutical companies - Ranbaxy, Hetero Drugs, Matrix Labs, and Strides to develop and market three new generic HIV/AIDS drugs in over 100 countries. The drugs are currently in final stages of clinical development. CNBC-TV18
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!